Display options
Share it on

J Musculoskelet Neuronal Interact. 2021 Dec 01;21(4):528-532.

Early and late apoptosis protein expression (Bcl-2, BAX and p53) in traumatic brachial plexus injury.

Journal of musculoskeletal & neuronal interactions

Heri Suroto, Asyumaredha Asriel, Brigita De Vega, Steven K Samijo

Affiliations

  1. Department of Orthopaedic & Traumatology, Dr. Soetomo General Hospital/Universitas Airlangga, Surabaya, Indonesia.
  2. Institute of Orthopaedic and Musculoskeletal Science, University College London, United Kingdom.
  3. Department of Orthopaedic, Zuyderland Medisch Centrum, Heerlen, Netherlands.

PMID: 34854392 PMCID: PMC8672401

Abstract

OBJECTIVES: This research aims to analyze the expression of pro-apoptotic proteins (Bax, p53) and anti-apoptotic protein (Bcl-2) in the nerve roots of the brachial plexus following traumatic brachial plexus injury (TBPI) in the early and late stage.

METHODS: A total of 30 biopsy samples were taken from the proximal stump of the postganglionic nerve roots of the TBPI patients' brachial plexus from January 2018 until September 2019. The samples were taken from patients within six months of trauma (early stage, group A) and more than six months following trauma (late stage, group B). Bcl-2, Bax, and p53 expressions in each group were measured and compared.

RESULTS: We found significant differences in the Bcl-2 (p=0.04), Bax (p<0.0001), p53 (p<0.0001) expressions between group A and B. The Bcl-2/Bax expression ratio in group A and B was 2.26 and 0.22, respectively. Meanwhile, the Bcl-2/p53 expression ratio in group A and B was 1.64 and 0.23, respectively.

CONCLUSION: Apoptosis is inhibited by Bcl-2 activities in the early stage following trauma. In the late stage, a significant decrease of Bcl-2 coupled with a substantial increase of Bax and p53 indicates a continuation of the apoptotic process.

Keywords: Anti-Apoptotic Protein; Brachial Plexus Neuropathies; Peripheral Nerve Injuries; Pro-Apoptotic Protein

Conflict of interest statement

The authors have no conflict of interest.

References

  1. Otol Neurotol. 2002 May;23(3):397-404 - PubMed
  2. Curr Opin Immunol. 2007 Oct;19(5):488-96 - PubMed
  3. Stroke. 2003 Jul;34(7):1803-8 - PubMed
  4. CNS Neurosci Ther. 2020 Feb;26(2):189-196 - PubMed
  5. Blood Res. 2018 Mar;53(1):53-60 - PubMed
  6. Ann Med Surg (Lond). 2021 Feb 17;63:102156 - PubMed
  7. Injury. 2020 Apr;51(4):787-803 - PubMed
  8. Stem Cell Res Ther. 2021 Jan 25;12(1):80 - PubMed
  9. Evid Based Complement Alternat Med. 2018 Feb 26;2018:8324696 - PubMed
  10. Orthopedics. 2017 Jan 1;40(1):e141-e156 - PubMed
  11. Cell Death Differ. 2000 Oct;7(10):868-79 - PubMed
  12. Curr Opin Neurobiol. 1998 Oct;8(5):613-8 - PubMed
  13. Br J Neurosurg. 2021 Jun;35(3):254-258 - PubMed
  14. Biochim Biophys Acta. 2010 Jan;1802(1):92-9 - PubMed
  15. EXCLI J. 2020 May 04;19:532-546 - PubMed
  16. J Reconstr Microsurg. 1998 Aug;14(6):423-36 - PubMed
  17. Mol Med Rep. 2017 Apr;15(4):2204-2212 - PubMed
  18. Plast Reconstr Surg. 1999 Oct;104(5):1221-40 - PubMed
  19. Zhonghua Yi Xue Za Zhi. 2000 Jul;80(7):530-3 - PubMed

Publication Types